Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis
Portal Hypertension &Cirrhosis, EarlyView.Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao +4 more
wiley +1 more source
Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives
Precision Medical Sciences, EarlyView.Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley +1 more source
A case report and a literature review of drug-induced liver injury caused by Huzhang according to the updated RUCAM. [PDF]
Medicine (Baltimore)Liang X, Yang X, Luo T, Dun W.
europepmc +1 more source
Boron‐10 carriers and their applications in boron neutron capture therapy
Precision Radiation Oncology, EarlyView.Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang +7 more
wiley +1 more source
Correction: Melaram et al. Microcystin Contamination and Toxicity: Implications for Agriculture and Public Health. <i>Toxins</i> 2022, <i>14</i>, 350. [PDF]
Toxins (Basel)Melaram R, Newton AR, Chafin J.
europepmc +1 more source
Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review
Phytotherapy Research, EarlyView.ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley +1 more source
Acute Hepatitis in a Patient Treated With Ribociclib for Metastatic Breast Carcinoma. [PDF]
J Med CasesIguh C, Bakhsh I, Grujic S.
europepmc +1 more source
Ashwagandha: Is It Safe? Part 1: A Regulatory Review
Phytotherapy Research, EarlyView.ABSTRACT Over the last decade, ashwagandha (Withania somnifera (L.) Dunal, AS) has been brought under increasing scrutiny by EU regulators regarding its safety for the use in food supplements, culminating in a recent recommendation for an Article 8 procedure according to Regulation (EC) No. 1925/2006 in the European Union (EU).
T. Brendler +5 more
wiley +1 more source
Mouse Models for the Study of Liver Fibrosis Regression In Vivo and Ex Vivo. [PDF]
J Clin Transl HepatolSchönke M, Rensen PCN.
europepmc +1 more source
Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha (Withania somnifera)
Phytotherapy Research, EarlyView.Sensoril, an aqueous root and leaf extract of ashwagandha showed no evidence of mutagenicity in the in vitro Ames assay, was negative in the in vitro micronucleus, in vivo mammalian bone marrow chromosome aberration assays, and was well tolerated in the rat at up to 4000 mg/kg BW/day when administered orally for a period of 90 days. The data from these
Mukesh Summan +2 more
wiley +1 more source